Our aim

​Positron emission tomography (PET) using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) is effective for tumour staging, prognosis, and treatment monitoring, but its use is limited due to ionising radiation, making it unsuitable for frequent use and for certain populations like children and pregnant women. ​ The DDG-MRI project aims to offer the benefits of FDG-PET without ionising radiation by using a novel MRI-based imaging agent, [D8]2-deoxy-D-glucose, and advanced deuterium MRI techniques. This approach promises higher spatial resolution and faster scan times, with a clinically acceptable dose. ​ The project involves six partners from five countries and aims to make this technology widely available for cancer detection and treatment monitoring.